Biomimetic

BioMimetic Therapeutics is a biotechnology company specializing in the development and commercialization of regenerative protein-device combination products for the repair of musculoskeletal injuries. The company's core technology is based on recombinant human Platelet-Derived Growth Factor (rhPDGF-BB), a potent stimulator of bone and soft tissue healing. Its lead products include GEM 21S, approved for periodontal regeneration, and Augment Bone Graft, designed for foot and ankle fusions. BioMimetic was a pioneer in the 'drug-device' combination space before being acquired by Wright Medical Group in 2013. Today, its technology continues to be a cornerstone of orthopedic biologics under Stryker's ownership.